Blood Purification最新文献

{"title":"Therapeutic Effects of Hemoperfusion in Treating Long-Acting Anticoagulant Rodenticide Poisoning.","authors":"Jianguang Dong, Bingling Yin, Jieyi Wu, Xiaobo Peng, Xiaoxia Lu, Zhongying Liu, Haojun Fan, Yanmei Zhao, Ziquan Liu, Zewu Qiu, Qiang Wen, Zhiguo Pan, Guodong Lin","doi":"10.1159/000552075","DOIUrl":"10.1159/000552075","url":null,"abstract":"<p><strong>Introduction: </strong>Second-generation anticoagulant rodenticides often cause severe bleeding that can be life threatening and have limited effective treatment options. This study aimed to evaluate the therapeutic efficacy of hemoperfusion in patients with rodenticide poisoning.</p><p><strong>Methods: </strong>We retrospectively analyzed data of 148 patients diagnosed with rodenticide poisoning at the Fifth Medical Center of the Chinese PLA General Hospital (China) between 2014 and 2021. The patients were divided into hemoperfusion and non-hemoperfusion groups based on whether or not they had received blood purification treatment. We compared clinical characteristics, serum drug concentrations, durations of hospital stay, and durations of vitamin K1 (VK1) therapy between the two groups using univariate and multivariate analyses. Subgroup analyses were also conducted to assess the effect of hemoperfusion in patients poisoned with brodifacoum and bromadiolone.</p><p><strong>Results: </strong>Of 148 screened patients, 115 patients were included (hemoperfusion [n = 24] and non-hemoperfusion [n = 91]). The rate of blood toxin clearance per unit time may have been faster in the hemoperfusion group. Subgroup analyses revealed that hemoperfusion significantly reduced the duration of VK1 therapy in patients poisoned with brodifacoum (p = 0.044).</p><p><strong>Conclusion: </strong>Hemoperfusion effectively reduced serum rodenticide concentrations in patients with poisoning. Moreover, hemoperfusion can reduce the duration of VK1 therapy in patients poisoned by brodifacoum.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148238745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intermittent Hemodialysis with Regional Citrate Anticoagulation versus Priming Heparin and Pre-Dilution HDF in Patients at Risk of Bleeding in Nephrology (The ROBIN Randomized Control Trial).","authors":"Olivier Moranne, Marion Gerbal, Sihame Chkair, Sylvain Cariou, Julien Prouvot, Pascal Reboul, Emilie Pambrun, Thierry Chevallier, Zihad Messikh","doi":"10.1159/000552412","DOIUrl":"10.1159/000552412","url":null,"abstract":"<p><strong>Introduction: </strong>This single-center randomized controlled trial (NCT03562754) compared pre-diluted IHDF (PIHDF) without systemic anticoagulation and the Prometheus system with regional citrate anticoagulation (RCA) in high-bleeding-risk patients.</p><p><strong>Methods: </strong>Intermittent hemodialysis (IHD) with RCA (IHD-RCA) with the Prometheus® device and PIHDF with a 5008H® dialysis monitor using priming and pre-dilution HDF online (25 mL/min) were compared in a 4-h IHD session for 60 high-bleeding-risk patients between 2019 and 2020. Bleeding risk was defined by a nephrologist. Successful hemodialysis was defined as no premature interruption of the 4-h session. We also analyzed adequacy (KT/V), dialyzer membrane status, cost, and organization from the nurse's viewpoint.</p><p><strong>Results: </strong>Eighty-two percent of patients were on chronic IHD and 41% had a fistula. Three patients in the IHD-RCA arm were excluded for early vascular access failure or persistent oral anticoagulation. No statistically significant difference was observed for the primary outcome between the two techniques (96% vs. 83%, p = 0.11). With PIHDF, 2 in 5 sessions failed after 3 h. No statistically significant difference in KT/V was observed between groups (1.69 vs. 1.61, p = 0.27), but a significantly higher mean blood flow for PIHDF was reached (294 vs. 263 mL/min, p < 0.001). The visual coagulation score was significantly worse for PIHDF (p < 0.01). No difference in clinical tolerance was found between groups. Hospital costs were higher with IHD-RCA than with PIHD, mainly due to the nurse's workload.</p><p><strong>Conclusion: </strong>Statistically, the primary outcome was not significantly different between techniques. The Prometheus device is efficient and clinically well tolerated, but PIHD is a cheaper, simpler procedure with little risk of coagulation if the session only lasts 3 h.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148203877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Double Filtration Plasmapheresis and Single Plasma Exchange in Patients with Lupus Nephritis: A Single-Center, Real-World Retrospective Study.","authors":"Pan Xie, Huan Chang, Kai Wen, Mei Sun, Hongwen Zhao, Jun Qiu, Yuxiu Sheng, Ning Yu, Claudio Ronco, Kanfu Peng, Xiaohui Liao","doi":"10.1159/000552429","DOIUrl":"10.1159/000552429","url":null,"abstract":"<p><strong>Introduction: </strong>Single plasma exchange (SPE) and double filtration plasmapheresis (DFPP) are commonly used in clinical practice. However, there have not been clear recommendations on the selection of SPE or DFPP for treating lupus nephritis (LN) in existing therapeutic PE guidelines. Therefore, this study aimed to evaluate the efficacy and safety of DFPP and SPE in patients with LN and to analyze the risk factors associated with ineffective DFPP and SPE treatment.</p><p><strong>Methods: </strong>In this single-center, real-world retrospective study, the safety and efficacy of therapy with SPE or DFPP were assessed in 67 patients with LN. Changes in laboratory test indicators and clinical parameters before and after treatment were compared, and the occurrence of adverse events (AEs) was observed in these patients.</p><p><strong>Results: </strong>Twenty-four patients were treated with DFPP and 43 patients with SPE. Both DFPP and SPE showed a significant treatment response. The effective rate of DFPP was higher than that of SPE (p < 0.05), but the difference was not statistically significant. In both groups, platelet count, potassium, chloride, activated partial thromboplastin time, and fibrinogen were significantly lower at baseline, and sodium was significantly higher at baseline (p < 0.05). The incidence of AEs in the DFPP group was lower than in the SPE group. The amount of plasma used in the DFPP group was significantly less than that in the SPE group during hospitalization. The economic cost of hospitalization or the remission rate did not differ significantly between the two groups. Length of hospital stay and serum creatinine were identified as risk factors for ineffective short-term PE in the treatment of LN.</p><p><strong>Conclusion: </strong>Both DFPP and SPE were effective and safe procedures for treating LN. However, DFPP does not depend on plasma and may reduce the incidence of adverse reactions; therefore, it should be promoted.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2026-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148194407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Point-of-Care Ultrasound in Post-Kidney Transplant Patients: Venous Excess Ultrasound Score and Lung Ultrasound for Fluid Assessment.","authors":"R Haridian Sosa Barrios, Irene Mínguez Toral, Víctor M Burguera Vion, Cristina Galeano Álvarez, Sandra Elías Triviño, Milagros Fernández Lucas, Maite E Rivera Gorrín","doi":"10.1159/000552658","DOIUrl":"10.1159/000552658","url":null,"abstract":"<p><strong>Introduction: </strong>Accurate volume assessment during the immediate post-kidney transplantation period reduces morbidity and mortality. Lung ultrasound (LUS), venous excess ultrasound score (VExUS), and bioimpedance analysis (BIA) are emerging methods for volume evaluation. We hypothesise LUS+VExUS may provide accurate means of congestion assessment in renal transplant patients, allowing more precise care.</p><p><strong>Method: </strong>An exploratory, prospective, single-centre pilot study was conducted. A prospective cohort (Group 1, n = 31) underwent volume assessment using a combined VExUS + LUS protocol on days +1 and +7 post-transplantation, alongside physical examination (PhE) and BIA. Findings were compared with a historical reference cohort (Group 2, n = 40) managed with standard clinical assessment alone.</p><p><strong>Results: </strong>Groups differed significantly in delayed graft function (45.2% vs. 15.0%, p = 0.008) and cold ischaemia time (p = 0.027). Acute pulmonary oedema occurred in 2/31 patients (6.5%) in Group 1 and 6/40 (15.0%) in Group 2, though this difference was not statistically significant (Fisher exact p = 0.452). VExUS showed no correlation with BIA (Spearman ρ = 0.127, p = 0.545), BNP (ρ = 0.187, p = 0.349), or Ca125 (ρ = 0.241, p = 0.226). VExUS detected venous congestion (grade ≥1) in 2/14 patients (14.3%) with normal PhE on Day +1. PhE showed poor agreement with VExUS (κ = 0.043) and moderate agreement with LUS (κ = 0.469). Combined ultrasound identified subclinical congestion in 28.6% of patients with normal PhE. Ultrasound findings prompted therapeutic modifications in 74.2% of cases on Day +1 (primarily IV fluid reduction) and 16.1% on Day +7.</p><p><strong>Conclusion: </strong>In this exploratory pilot study, VExUS and LUS provided additional diagnostic information beyond PhE and influenced clinical decision-making in the majority of cases. These hypothesis-generating findings warrant confirmation in larger, multicentre, prospective studies with standardised protocols.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Continuous Renal Replacement Therapy Filters with Cytokine Adsorption Properties on Survival Outcomes: A Study Using Diagnosis Procedure Combination Data.","authors":"Masahiro Hyodo, Toshikazu Yogai, Ryota Kawai, Kanae Takahashi, Hisako Yoshida, Ayumi Shintani","doi":"10.1159/000552487","DOIUrl":"10.1159/000552487","url":null,"abstract":"<p><strong>Introduction: </strong>Continuous renal replacement therapy (CRRT) is one of the adjunctive therapies for sepsis. In Japan, the polyethyleneimine-coated polyacrylonitrile membrane (AN69ST) with cytokine adsorption properties was approved in 2014. This study compared 30-day mortality between conventional hemofilter and AN69ST in patients who underwent CRRT in intensive care unit (ICU).</p><p><strong>Methods: </strong>Using the Diagnosis Procedure Combination (DPC) database provided by Medical Data Vision Co., Ltd. (MDV), our analysis focused on patients who underwent CRRT in ICU from April 1, 2014. The primary outcome was defined as the 30-day mortality rate following the initiation of CRRT treatment. Patients were categorized into two groups: the AN69ST group, in whom CRRT was initiated with AN69ST, and the non-AN69ST group, in whom CRRT was initiated with membranes other than AN69ST. A subgroup analysis was performed to assess whether the effect of AN69ST differed based on the presence or absence of a sepsis diagnosis, and treatment interaction was also evaluated. Furthermore, analysis was conducted considering changes in hemofilters to align with actual clinical practice.</p><p><strong>Results: </strong>A total of 9,147 patients underwent CRRT, including 7,728 in the non-AN69ST group and 1,419 in the AN69ST group. The median age was 72 years. The analysis demonstrated significantly lower 30-day mortality in the AN69ST group (hazard ratio [HR] 0.825, 95% confidence interval [CI] 0.744-0.916) compared with the non-AN69ST group. Subgroup analysis revealed a more pronounced reduction in mortality in the sepsis subgroup (HR 0.781, 95% CI: 0.690-0.884).</p><p><strong>Conclusion: </strong>The results of this study suggest that AN69ST membrane use was associated with lower 30-day mortality after the initiation of treatment. The results remained consistent even after considering changes in hemofilter.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148004523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Double-Filtration Plasmapheresis for ABO-Incompatible Living-Donor Kidney Transplantation.","authors":"Xiaochun Zhou, Youmin Yang, Yingying Yang, Yunying Shi, Xi Tang, Xu Li, Fang Wang, Ping Fu, Xianding Wang, Ling Zhang","doi":"10.1159/000552433","DOIUrl":"10.1159/000552433","url":null,"abstract":"<p><strong>Introduction: </strong>ABO-incompatible (ABOi) kidney transplantation (KT) is now an established form of renal replacement therapy. However, it is important to note that ABO antibody clearance affects the procedure's success. As demonstrated in prior studies, both double-filtration plasmapheresis (DFPP) and plasma exchange (PE) can eliminate IgM and IgG isoagglutinins. However, relatively few studies have examined the long-term prognosis in patients with both conditions. The present study aimed to compare the efficacy and long-term prognosis of DFPP with those of PE in patients with ABOi-KT.</p><p><strong>Methods: </strong>From September 2014 to April 2024, 230 consecutive ABOi living-donor KTs were performed. The participants were divided into DFPP and PE groups. Following propensity score matching (PSM), the primary outcomes included acute rejection (AR), infection, graft loss, patient death, and the effects of the two modalities on isoagglutinin titers (IgG and IgM).</p><p><strong>Results: </strong>After 1:4 PSM, a total of 24 patients in the PE group and 63 patients in the DFPP group were included in the final analysis. Compared with PE, DFPP was associated with a significantly lower incidence of 6-month AR (6.3% vs. 33.3%, p = 0.003) and 6-month patient mortality (0% vs. 12.5%, p = 0.019), along with shorter hospital stays (22 [18-29] vs. 42 [36-48] days, p < 0.001). Multifactorial analysis revealed that the risk of AR in ABOi-KTs with antibody rebound was 6.43 times greater than that in ABOi-KTs without antibody rebound (OR = 6.43, 95% CI: 1.21-34.1, p = 0.029), whereas the risk of AR in ABOi-KTs pretreated with DFPP was 85.8% lower than that in ABOi-KTs pretreated with PE (OR = 0.142, 95% CI: 0.04-0.57, p = 0.006). However, no statistically significant differences were observed between the two groups in 6-month creatinine levels or 6-month graft loss. No significant differences were observed between the two groups in the reduction of IgG and IgM isoagglutinins. A single PE session led to a reduction in the IgM isoagglutinin titer by approximately 3-fold, in comparison with a 2-fold reduction that was observed with a single session of DFPP. Similarly, a single PE session led to a 2-fold reduction in IgG isoagglutinin titer. DFPP sessions resulted in a reduction that was marginally less than 2-fold. It is noteworthy that DFPP exhibited a more pronounced depletion of albumin (10.6 ± 6.7 vs. 4.8 ± 5.5 g/L, p < 0.001), globulin (10.4 ± 6.5 vs. 5.5 ± 5.7 g/L, p = 0.002), and fibrinogen (1.5 [1.2-2.2] vs. 1.1 [0.1-1.9] g/L, p = 0.024).</p><p><strong>Conclusions: </strong>Compared with PE, DFPP might be more advantageous in the ABOi-KT preconditioning regimen, but close monitoring of fibrinogen, albumin, and globulin is needed.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2026-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147959674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney Health for All: Caring for People, Protecting the Planet.","authors":"Raymond Vanholder, Dina Abdellatif, Augusto Cesar Soares Dos Santos, Ricardo Correa-Rotter, Natarajan Gopalakrishnan, Bill Wang, Stefanos Roumeliotis, Alessandro Balducci, Ágnes Haris, Manjusha Yadla, Li-Li Hsiao","doi":"10.1159/000552460","DOIUrl":"10.1159/000552460","url":null,"abstract":"","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Algorithm-Driven Analytics and Clinical Decision Support in Remote Monitoring in Automated Peritoneal Dialysis: Patient and Clinician Experiences.","authors":"Maria Paz Dazzarola, Javier Enrique Cely, Cesar Doria, Juan C Castillo, Jorge A Pulido, Fabio Rojas, Mauricio Sanabria, Jasmin Vesga, Yolima Alba, Bengt Lindholm, Angela Rivera, Peter Rutherford","doi":"10.1159/000552265","DOIUrl":"10.1159/000552265","url":null,"abstract":"<p><strong>Introduction: </strong>Remote monitoring programs for kidney failure patients undergoing automated peritoneal dialysis (APD-RMP) are increasing worldwide and improving clinical outcomes. This study evaluated both patient-reported perceptions and experiences of healthcare professionals when using the new Sharesource Analytics 1.0 APD-RMP platform and generated proposals for easily implemented decision rules.</p><p><strong>Methods: </strong>This prospective observational study of 284 adult patients receiving APD-RMP and switching to the Sharesource Analytics 1.0 platform was conducted from March 1 to April 12, 2024, in six dialysis centers. Patient-reported experience was measured using the Kidney PREM survey, and healthcare usability was measured using the Telehealth Usability Questionnaire. Expert consensus and focus group techniques were used to create decision rules in response to data presented in the Sharesource Analytics 1.0 platform.</p><p><strong>Results: </strong>Patients rated their overall experience with the service provided by their dialysis center at the end of the study period as 6.9 (SD 0.3), with seven being the best possible score. Nephrologists and nurses rated their satisfaction with the new tool at 6.8 (SD 0.3) and its usability at 6.8 (SD 0.3); the maximum possible score was 7. Twenty-seven healthcare professionals (20 women), including nephrologists and nurses, participated in the expert consensus and focus group, which - based on type of alarm, findings and causes, and review of possible actions - proposed decision rules for interventions.</p><p><strong>Conclusion: </strong>Care delivered using a remote monitoring platform with analytics was associated with high patient-reported experience ratings and very good usability and satisfaction ratings from healthcare professionals. Integrating structured decision rules alongside remote analytics could facilitate a more proactive, personalized, and efficient APD-RMP care.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-14"},"PeriodicalIF":2.2,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13327667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147761242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting D-Dimer and Fibrin(ogen) Degradation Products in Hemodialysis Vascular Access Surveillance.","authors":"Min Li, Xiaoli Fan, Xinru Du, Aihui Li, Zhanyun Zhao, Jing Du","doi":"10.1159/000552076","DOIUrl":"10.1159/000552076","url":null,"abstract":"<p><strong>Background: </strong>Vascular access dysfunction remains a major source of morbidity and repeat procedures in maintenance hemodialysis (HD), with thrombosis as a key proximate event. D-dimer and fibrin(ogen) degradation products (FDPs) are widely available readouts of downstream fibrin(ogen) turnover, but they are not routinely used for access surveillance and are often difficult to interpret in HD.</p><p><strong>Summary: </strong>This narrative review summarizes HD-specific biology relevant to fibrin turnover and synthesizes clinical evidence linking D-dimer and FDP to access outcomes across arteriovenous fistulas, grafts, and catheters. HD promotes a prothrombotic, hypofibrinolytic profile through uremia-related endothelial disturbance, chronic inflammation, and extracorporeal circuit effects. The clinical literature is mostly small and heterogeneous in assay platforms, sampling, and outcome definitions. Across cohorts, repeated pre-dialysis measurements may provide more interpretable within-patient context than single measurements, although longitudinal HD access-specific evidence remains limited. Interpretation remains constrained by assay and unit variability and by non-access-related influences such as inflammation and intercurrent illness. Accordingly, D-dimer and FDP are best used as contextual adjuncts within an imaging- and hemodynamics-based framework, interpreted alongside access flow measures, duplex ultrasound, and clinical assessment.</p><p><strong>Key messages: </strong>In HD access, repeated pre-dialysis measurements may provide more interpretable within-patient context than one-off D-dimer/FDP values, although direct longitudinal evidence remains limited. Assay and unit heterogeneity, plus systemic confounding, limit portability and access-specific interpretation. Biomarkers are best read as supportive context alongside hemodynamic measures and clinical assessment, not as stand-alone surveillance tools. Imaging-anchored prospective studies with standardized sampling and explicit assay/unit reporting are needed to define added value.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147761221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemoadsorption: One Name, Varied Techniques.","authors":"Stefano Romagnoli, Gianluca Villa, Francesco Barbani, Zaccaria Ricci","doi":"10.1159/000545741","DOIUrl":"10.1159/000545741","url":null,"abstract":"<p><strong>Background: </strong>Despite significant efforts to improve outcomes for patients with sepsis and septic shock, mortality rates remain alarmingly high.</p><p><strong>Summary: </strong>Beyond standard management, novel adjuvant treatments seek to improve outcomes through a personalized approach. Among these, immunomodulation strategies aim to reestablish a balance in the dysregulated immune system, managing both pro-inflammatory and anti-inflammatory mediators. In recent years, various techniques utilizing extracorporeal circuits equipped with filters or cartridges, collectively referred to as blood purification therapies, have been developed and introduced to the market. Hemoadsorption, whether used alone or in conjunction with hemofiltration, may clear a broad range of substances from the blood, including inflammatory mediators, drugs, trace elements, bacteria, and viruses.</p><p><strong>Key messages: </strong>Understanding the fundamental principles of blood purification techniques is essential for enhancing survival probabilities, keeping in mind the principle of primum non nocere as a guiding tenet of our daily practice. This review aimed to give an overview of hemoadsorption techniques by presenting current evidence and highlighting key areas that require further investigation.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"331-339"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}